Azithromycin distinctively modulates classical activation of human monocytes in vitro

Abstract

BACKGROUND AND PURPOSEAzithromycin has been reported to modify activation of macrophages towards the M2 phenotype. Here, we have sought to identify the mechanisms underlying this modulatory effect of azithromycin on human monocytes, classically activated in vitro. EXPERIMENTAL APPROACHHuman blood monocytes were primed with IFN-g for 24 h and activated with LPS for 24 h. Azithromycin, anti-inflammatory and lysosome-affecting agents were added 2 h before IFN-g. Cytokine and chemokine expression was determined by quantitative PCR and protein release by ELISA. Signalling molecules were determined by Western blotting and transcription factor activation quantified with a DNA-binding ELISA kit. KEY RESULTSAzithromycin (1.5-50 mM) dose-dependently inhibited gene expression and/or release of M1 macrophage markers (CCR7, CXCL 11 and IL-12p70), but enhanced CCL2, without altering TNF-a or IL-6. Azithromycin also enhanced the gene expression and/or release of M2 macrophage markers (IL-10 and CCL18), and the pan-monocyte marker CD163, but inhibited that of CCL22. The Toll-like receptor (TLR) 4 signalling pathway was modulated, down-regulating NF-kB and STAT1 transcription factors. The inhibitory profile of azithromycin differed from that of dexamethasone, the phosphodiesterase-4 inhibitor roflumilast and the p38 kinase inhibitor SB203580 but was similar to that of the lysosomotropic drug chloroquine. Effects of concanamycin and NH4Cl, which also act on lysosomes, differed significantly. CONCLUSIONS AND IMPLICATIONSAzithromycin modulated classical activation of human monocytes by inhibition of TLR4-mediated signalling and possible effects on lysosomal function, and generated a mediator expression profile that differs from that of monocyte/macrophage phenotypes so far described.

Direct and Indirect Anti-Inflammatory Effects of Tulathromycin in Bovine Macrophages: Inhibition of CXCL-8 Secretion, Induction of Apoptosis, and Promotion of Efferocytosis

“…Similarly, azithromycin promotes the phagocytic clearance of apoptotic neutrophils and bronchial epithelial cells by macrophages, an effect that is partially dependent on PS receptor binding (40). Moreover, azithromycin was shown to modify activation of macrophages toward the M2 anti-inflammatory phenotype (41,42), possibly via inhibition of Toll-like receptor 4 (TLR4)-mediated NF-B signaling (43).…”

Neuroprotective Properties of a Macrolide Antibiotic in a Mouse Model of Middle Cerebral Artery Occlusion: Characterization of the Immunomodulatory Effects and Validation of the Efficacy of Intravenous Administration

“…In fact, preservation of alternatively activated M2 microglia/macrophages promotes neuronal survival and functional recovery under ischemic/hypoxic conditions. [8][9][10][86][87][88] The mechanism by which azithromycin shifts macrophages from the classically activated (M1) to the alternatively activated (M2) phenotype has not been completely elucidated [89][90][91] ; however, AP-1 activation and impairment of lysosomal functions may be probably involved. 92,93 These immunomodulatory properties contribute to the clinical efficacy of azithromycin in respiratory diseases, 25 whereas their relevance in neurodegenerative conditions has only been partially explored.…”

Macrolides for the treatment of chronic bacterial prostatitis: An effective application of their unique pharmacokinetic and pharmacodynamic profile (Review)

“…NFκB and STAT1 transcription factors in the TLR4 signalling pathway were down-regulated (56). These effects are likely to facilitate the removal of phagocytosed bacteria and the resolution of chronic inflammation, a possibility that may also apply to CBP.…”